<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ipilimumab: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ipilimumab: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ipilimumab: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="16084" href="/d/html/16084.html" rel="external">see "Ipilimumab: Drug information"</a> and <a class="drug drug_patient" data-topicid="16460" href="/d/html/16460.html" rel="external">see "Ipilimumab: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F12743392"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Yervoy</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871222"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Yervoy</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F28120061"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antineoplastic Agent, Monoclonal Antibody</span></li></ul></div>
<div class="block dop drugH1Div" id="F50487014"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="769d5e2a-1b38-4db1-88c9-3311a2a0e438">Colorectal cancer, metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Colorectal cancer, metastatic (microsatellite instability-high [MSI-H] or mismatch repair deficient [dMMR]): Note:</b> FDA approval for MSI-H or dMMR metastatic colorectal cancer is through an accelerated process; continued approval is dependent upon verification of clinical benefit in further trials.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: IV: 1 mg/kg every 3 weeks (in combination with nivolumab) for up to 4 doses.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5b8b61a8-a96f-4706-a076-2ede2ffc94b3">Melanoma, unresectable or metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Melanoma, unresectable or metastatic:</b>
<b>Note:</b> May be used as a single agent or in combination with nivolumab.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: IV: 3 mg/kg every 3 weeks for a maximum of 4 doses (or fewer if unacceptable toxicity occurs).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7177d86f-32ee-49d7-9ed7-ee88e7f0a1c0">Solid tumors, relapsed/refractory</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Solid tumors, relapsed/refractory: </b>Very limited data available: <b></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Combination therapy with nivolumab: </i></p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥4 years and Adolescents: IV: 1 mg/kg every 3 weeks (in combination with nivolumab) for 4 doses (or less if unacceptable toxicity occurs) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36190525']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36190525'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for toxicity:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> No dosage reductions of ipilimumab are recommended. When ipilimumab is given in combination with nivolumab, withhold or permanently discontinue both ipilimumab and nivolumab for an adverse reaction meeting dosage modification recommendations. Refer to Nivolumab monograph for information on nivolumab dosage adjustment for toxicity. Other concomitant combination therapy medications may also require treatment interruption, dosage reduction, and/or discontinuation.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Immune-mediated adverse reactions (general information):</b> Withhold ipilimumab for severe (grade 3) immune-mediated adverse reactions. Permanently discontinue ipilimumab for life-threatening (grade 4) immune-mediated adverse reactions, recurrent severe (grade 3) immune-mediated reactions that require systemic immunosuppressive treatment, persistent moderate (grade 2) or severe (grade 3) reactions lasting 12 weeks or longer beyond the last ipilimumab dose (excluding endocrinopathies), or inability to reduce corticosteroid dose to prednisone ≤10 mg/day (or equivalent) within 12 weeks of initiating corticosteroids. If ipilimumab treatment interruption or discontinuation is required, administer systemic corticosteroid therapy (1 to 2 mg/kg/day prednisone [or equivalent]) until improvement to ≤ grade 1; upon improvement to grade 1 or lower, initiate corticosteroid taper and continue to taper over at least 1 month. Consider administration of other systemic immunosuppressants if immune-mediated adverse reaction is not controlled with corticosteroid therapy. Systemic corticosteroids may not be necessary for certain adverse reactions. Hormone replacement therapy may be required for endocrinopathies (if clinically indicated). See table for additional dosage modification guidance.</p>
<table border="1" frame="border" rules="all">
<caption style="text-align:center;">
<b>Ipilimumab Recommended Dosage Modifications for Adverse Reactions</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:center;">
<b>Adverse reaction</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:center;">
<b>Severity</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:center;">
<b>Ipilimumab dosage modification</b></p></th></tr></thead>
<tfoot>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:left;">
<sup>a </sup>SJS = Stevens-Johnson syndrome; TEN = toxic epidermal necrolysis; DRESS = drug rash with eosinophilia and systemic symptoms.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:center;">
<b>Immune-mediated adverse reactions</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Cardiovascular toxicity: Myocarditis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 2, 3, or 4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Permanently discontinue ipilimumab.</p></td></tr>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;text-align:left;">Dermatologic toxicity</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Mild to moderate nonbullous/exfoliative rash</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">May be managed with topical emollients and/or topical corticosteroids. Withhold or permanently discontinue ipilimumab depending on severity.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Exfoliative dermatologic conditions: Suspected SJS, TEN, or DRESS<sup>a</sup></p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Withhold ipilimumab.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Confirmed SJS, TEN, or DRESS</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Permanently discontinue ipilimumab.</p></td></tr>
<tr>
<td align="center" rowspan="6">
<p style="text-indent:0em;text-align:left;">Endocrinopathies</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 2</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Depending on clinical severity, consider withholding until symptom improvement with hormone replacement. Resume once acute symptoms have resolved.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 3 or 4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Withhold ipilimumab if not clinically stable. Moderate and life-threatening endocrinopathy may require long-term hormone replacement therapy (eg, adrenal or thyroid hormone therapy).</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Adrenal insufficiency</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Withhold or discontinue ipilimumab (depending on the severity). Initiate medical management as clinically indicated.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Hypophysitis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Withhold or discontinue ipilimumab (depending on the severity).</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Hyperthyroidism</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Withhold or discontinue ipilimumab (depending on the severity). Initiate medical management as clinically indicated.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Hypothyroidism</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Withhold ipilimumab (depending on the severity). Initiate thyroid hormone replacement therapy as clinically indicated.</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;text-align:left;">GI toxicity: Colitis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 2</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Withhold ipilimumab; resume ipilimumab after complete or partial (to grade 0 or 1) resolution after corticosteroid taper. Permanently discontinue ipilimumab if no complete or partial response within 12 weeks of last ipilimumab dose, or if unable to reduce prednisone to &lt;10 mg/day (or equivalent) within 12 weeks of corticosteroid initiation.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 3 or 4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Permanently discontinue ipilimumab.</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;text-align:left;">Neurologic toxicities</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 2</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Withhold ipilimumab; resume ipilimumab after complete or partial (to grade 0 or 1) resolution after corticosteroid taper. Permanently discontinue ipilimumab if no complete or partial response within 12 weeks of last ipilimumab dose, or if unable to reduce prednisone to &lt;10 mg/day (or equivalent) within 12 weeks of corticosteroid initiation.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 3 or 4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Permanently discontinue ipilimumab.</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;text-align:left;">Ophthalmic toxicity</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 2, 3, or 4 that does not improve to grade 1 within 2 weeks while receiving topical therapy <b>or</b> that requires systemic treatment</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Permanently discontinue ipilimumab.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Vogt-Koyanagi-Harada-like syndrome</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">May require systemic corticosteroids to reduce the risk of permanent vision loss.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Pancreatitis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 3 or 4 amylase or lipase increases</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Permanent ipilimumab discontinuation is recommended (Weber 2012).</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;text-align:left;">Pulmonary toxicity: Pneumonitis</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 2</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Withhold ipilimumab; resume ipilimumab after complete or partial (to grade 0 or 1) resolution after corticosteroid taper. Permanently discontinue ipilimumab if no complete or partial response within 12 weeks of last ipilimumab dose, or if unable to reduce prednisone to &lt;10 mg/day (or equivalent) within 12 weeks of corticosteroid initiation.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 3 or 4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Permanently discontinue ipilimumab.</p></td></tr>
<tr>
<td align="center" colspan="3">
<p style="text-indent:0em;text-align:center;">
<b>Other adverse reactions</b></p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;text-align:left;">Infusion reactions</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 1 or 2</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Interrupt or slow the rate of ipilimumab infusion.</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:center;">Grade 3 or 4</p></td>
<td align="center">
<p style="text-indent:0em;text-align:center;">Permanently discontinue ipilimumab.</p></td></tr></tbody></table></div>
<div class="block dorp drugH1Div" id="F51159593"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children ≥12 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Baseline kidney impairment: </b></p>
<p style="text-indent:-2em;margin-left:4em;">GFR ≥15 mL/minute/1.73 m<sup>2</sup>: There are no dosage adjustments provided in the manufacturer's labeling; however, GFR ≥15 mL/minute/1.73 m<sup>2</sup> had no clinically important effect on ipilimumab clearance.</p>
<p style="text-indent:-2em;margin-left:4em;">GFR &lt;15 mL/minute/1.73 m<sup>2</sup>: There are no dosage adjustments provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Nephrotoxicity during treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immune-mediated nephritis with kidney dysfunction:</i> If ipilimumab treatment interruption or discontinuation is required, administer systemic corticosteroids (1 to 2 mg/kg/day prednisone [or equivalent]) or other appropriate therapy for immune-mediated adverse reactions until improvement to grade 1 or lower, then follow with a corticosteroid taper.</p>
<p style="text-indent:-2em;margin-left:6em;">Grade 2 or grade 3 serum creatinine elevation: Withhold ipilimumab; resume ipilimumab after complete or partial (to grade 0 or 1) resolution after corticosteroid taper. Permanently discontinue ipilimumab if no complete or partial response within 12 weeks of last ipilimumab dose, or if unable to reduce prednisone to &lt;10 mg/day (or equivalent) within 12 weeks of corticosteroid initiation.</p>
<p style="text-indent:-2em;margin-left:6em;">Grade 4 serum creatinine elevation: Permanently discontinue ipilimumab.</p></div>
<div class="block dohp drugH1Div" id="F51159594"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children ≥12 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Baseline hepatic impairment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Mild impairment (total bilirubin &gt;1 to 1.5 times ULN <b>or</b> AST &gt;ULN): There are no dosage adjustments provided in the manufacturer's labeling; however, mild impairment had no clinically important effect on ipilimumab clearance.</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate or severe impairment (total bilirubin &gt;1.5 times ULN and any AST): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatotoxicity during treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">If ipilimumab treatment interruption or discontinuation is required, administer systemic corticosteroids (1 to 2 mg/kg/day prednisone [or equivalent]) or other appropriate therapy for immune-mediated adverse reactions until improvement to grade 1 or lower, then follow with a corticosteroid taper. Permanently discontinue ipilimumab if no complete or partial response within 12 weeks of last ipilimumab dose, or if unable to reduce prednisone to &lt;10 mg/day (or equivalent) within 12 weeks of corticosteroid initiation.</p>
<p style="text-indent:-2em;margin-left:4em;">If transaminases do not decrease within 48 hours of steroid initiation, consider adding mycophenolate mofetil; may begin tapering corticosteroid (over 1 month) when LFTs show sustained improvement or return to baseline (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22614989']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22614989'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immune-mediated hepatitis <b> without</b> tumor involvement of the liver or hepatitis with tumor involvement of the liver/non-hepatocellular carcinoma:</i></p>
<p style="text-indent:-2em;margin-left:6em;">AST or ALT &gt;3 to ≤5 times ULN <b>or</b> total bilirubin &gt;1.5 to ≤3 times ULN: Withhold ipilimumab; resume ipilimumab with complete or partial resolution (to grade 0 or 1) of hepatitis after corticosteroid taper.</p>
<p style="text-indent:-2em;margin-left:6em;">AST or ALT &gt;5 times ULN <b>or</b> total bilirubin &gt;3 times ULN: Permanently discontinue ipilimumab.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immune-mediated hepatitis <b>with</b> tumor involvement of the liver/hepatocellular carcinoma (applies to hepatocellular carcinoma ipilimumab/nivolumab combination treatment):</i>
<b>Note: </b>When receiving combination therapy with ipilimumab and nivolumab, withhold or permanently discontinue both ipilimumab and nivolumab for adverse reactions meeting dosage modification recommendations (refer to Nivolumab monograph for information on nivolumab dosage adjustment for toxicity). If AST and ALT are ≤ ULN at baseline, follow recommendations for hepatitis <b>without</b> tumor involvement of the liver.</p>
<p style="text-indent:-2em;margin-left:6em;">If baseline AST or ALT &gt;1 to ≤3 times ULN and increases to &gt;5 to ≤10 times ULN or baseline AST or ALT &gt;3 to ≤5 times ULN and increases to &gt;8 to ≤10 times ULN: Withhold treatment. Resume treatment with complete or partial resolution (to grade 0 or 1) of hepatitis after corticosteroid taper.</p>
<p style="text-indent:-2em;margin-left:6em;">AST or ALT &gt;10 times ULN or total bilirubin &gt;3 times ULN: Discontinue permanently.</p></div>
<div class="block doa drugH1Div" id="F10940812"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="16084" href="/d/html/16084.html" rel="external">see "Ipilimumab: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> When ipilimumab is used in combination with nivolumab, refer to Nivolumab monograph for nivolumab dosing information.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f2c27f86-343d-4fc1-b682-3d3185358f12">Colorectal cancer, metastatic, microsatellite instability-high or mismatch repair deficient</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Colorectal cancer, metastatic, microsatellite instability-high or mismatch repair deficient: IV:</b> 1 mg/kg once every 3 weeks (in combination with nivolumab) for 4 combination doses, followed by nivolumab monotherapy until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29355075']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29355075'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="83f54cd5-965e-4621-916e-cb8419aedcbc">Esophageal carcinoma, squamous cell, unresectable advanced or metastatic; first-line therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Esophageal carcinoma, squamous cell, unresectable advanced or metastatic; first-line therapy:</b>
<b>IV:</b> 1 mg/kg once every 6 weeks (in combination with nivolumab) until disease progression or unacceptable toxicity, or up to 2 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35108470']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35108470'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b12c5cbe-89c2-4211-ab16-15d280500cad">Hepatocellular carcinoma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatocellular carcinoma: IV:</b> 3 mg/kg once every 3 weeks (in combination with nivolumab) for 4 combination doses, followed by nivolumab monotherapy until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Pau.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Pau.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="431f299e-6233-427d-8878-9a1a390368b5">Malignant pleural mesothelioma, unresectable; first-line therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Malignant pleural mesothelioma, unresectable; first-line therapy: IV:</b> 1 mg/kg once every 6 weeks (in combination with nivolumab) until disease progression, unacceptable toxicity, or for up to 2 years in patients without disease progression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33485464','lexi-content-ref-35124183']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33485464','lexi-content-ref-35124183'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0dd192c0-c0ab-4a8a-b7ed-b87c271ab08a">Melanoma, adjuvant treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Melanoma, adjuvant treatment:</b>
<b>IV:</b> 10 mg/kg every 3 weeks for up to 4 doses, followed by 10 mg/kg every 12 weeks for up to 3 years unless disease progression or unacceptable toxicity occur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27717298']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27717298'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Off-label dosing: </i>
<b>IV:</b> 3 mg/kg once every 3 weeks for 4 doses (induction), followed by 3 mg/kg once every 12 weeks for up to 4 additional doses (maintenance) or until disease progression or unacceptable toxicity for up to a maximum of 60 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31880964']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31880964'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="aeec307b-eed5-46db-b70e-c80ed1273f2e">Melanoma, unresectable or metastatic, single-agent therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Melanoma, unresectable or metastatic, single-agent therapy:</b>
<b>IV:</b> 3 mg/kg every 3 weeks for a maximum of 4 doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20525992']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20525992'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2be326df-c372-47be-b2e3-e4007963d056">Melanoma, unresectable or metastatic, combination therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Melanoma, unresectable or metastatic, combination therapy:</b>
<b>IV:</b> 3 mg/kg every 3 weeks (in combination with nivolumab) for a maximum of 4 combination doses (or until unacceptable toxicity, whichever occurs first); followed by nivolumab monotherapy until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26027431','lexi-content-ref-31562797']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26027431','lexi-content-ref-31562797'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e334c046-bd21-4072-8013-1dad74f4b375">Melanoma, with brain metastases</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Melanoma, with brain metastases (off-label use):</b>
<b>IV:</b> 3 mg/kg once every 3 weeks (in combination with nivolumab) for 4 combination doses, followed by nivolumab monotherapy; total duration of nivolumab therapy is up to 24 months, or until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30134131']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30134131'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a03fc737-51ba-437f-8914-2c99d7fee888">Merkel cell carcinoma, unresectable, recurrent, or stage IV</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Merkel cell carcinoma, unresectable, recurrent, or stage IV (off-label use): IV: </b>1 mg/kg once every 6 weeks (in combination with nivolumab) until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36108657']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36108657'])">Ref</a></span>). <b></b></p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cd3ed7f0-b224-41ae-8fa2-3df372f1d8bc">Non–small cell lung cancer, metastatic, PD-L1-expressing</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Non–small cell lung cancer, metastatic, PD-L1-expressing: IV:</b> 1 mg/kg once every 6 weeks (in combination with nivolumab) until disease progression, unacceptable toxicity, or up to 2 years in patients without disease progression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31562796']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31562796'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f255d5ce-fe57-463a-a9be-47206170344c">Non–small cell lung cancer, metastatic or recurrent</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Non–small cell lung cancer, metastatic or recurrent: IV:</b> 1 mg/kg once every 6 weeks (in combination with nivolumab and 2 cycles of histology-based platinum-doublet chemotherapy) until disease progression, unacceptable toxicity, or up to 2 years in patients without disease progression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33476593']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33476593'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4bd59ae1-8548-4c76-8978-10cf31a1992a">Renal cell cancer, advanced, first-line combination therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Renal cell cancer, advanced, first-line combination therapy:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>May be used in combination with nivolumab in patients with intermediate- or poor-risk disease, and the combination may also be considered (off label) in patients with favorable-risk disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35728020','lexi-content-ref-Atkins.1','lexi-content-ref-George.1','lexi-content-ref-31427204']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35728020','lexi-content-ref-Atkins.1','lexi-content-ref-George.1','lexi-content-ref-31427204'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 1 mg/kg once every 3 weeks (in combination with nivolumab) for a maximum of 4 combination doses, followed by nivolumab monotherapy until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31427204','lexi-content-ref-29562145']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31427204','lexi-content-ref-29562145'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991576"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Renal impairment at baseline: </b></p>
<p style="text-indent:-2em;margin-left:4em;">GFR ≥15 mL/minute/1.73 m<sup>2</sup>: There are no dosage adjustments provided in the manufacturer's labeling; however, GFR ≥15 mL/minute/1.73 m<sup>2</sup> had no clinically important effect on ipilimumab clearance.</p>
<p style="text-indent:-2em;margin-left:4em;">GFR &lt;15 mL/minute/1.73 m<sup>2</sup>: There are no dosage adjustments provided in the manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Renal toxicity during treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immune-mediated nephritis with kidney dysfunction:</i> If ipilimumab treatment interruption or discontinuation is required, administer systemic corticosteroids (1 to 2 mg/kg/day prednisone [or equivalent]) or other appropriate therapy for immune-mediated adverse reactions until improvement to grade 1 or lower, then follow with a corticosteroid taper.</p>
<p style="text-indent:-2em;margin-left:6em;">Grade 2 or grade 3 serum creatinine elevation: Withhold ipilimumab; resume ipilimumab after complete or partial (to grade 0 or 1) resolution after corticosteroid taper. Permanently discontinue ipilimumab if no complete or partial response within 12 weeks of last ipilimumab dose, or if unable to reduce prednisone to &lt;10 mg/day (or equivalent) within 12 weeks of corticosteroid initiation.</p>
<p style="text-indent:-2em;margin-left:6em;">Grade 4 serum creatinine elevation: Permanently discontinue ipilimumab.</p></div>
<div class="block doha drugH1Div" id="F50988750"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatic impairment at baseline:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Mild impairment (total bilirubin &gt;1 to 1.5 x ULN <b>or</b> AST &gt;ULN): There are no dosage adjustments provided in the manufacturer's labeling; however, mild impairment had no clinically important effect on ipilimumab clearance.</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate or severe impairment (total bilirubin &gt;1.5 x ULN and any AST): There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatotoxicity during treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">If ipilimumab treatment interruption or discontinuation is required, administer systemic corticosteroids (1 to 2 mg/kg/day prednisone [or equivalent]) or other appropriate therapy for immune-mediated adverse reactions until improvement to grade 1 or lower, then follow with a corticosteroid taper. Permanently discontinue ipilimumab if no complete or partial response within 12 weeks of last ipilimumab dose, or if unable to reduce prednisone to &lt;10 mg/day (or equivalent) within 12 weeks of corticosteroid initiation.</p>
<p style="text-indent:-2em;margin-left:4em;">If transaminases do not decrease within 48 hours of steroid initiation, consider adding mycophenolate mofetil; may begin tapering corticosteroid (over 1 month) when LFTs show sustained improvement or return to baseline (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22614989']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22614989'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immune-mediated hepatitis <b> without</b> tumor involvement of the liver or hepatitis with tumor involvement of the liver/non-hepatocellular carcinoma:</i></p>
<p style="text-indent:-2em;margin-left:6em;">AST or ALT &gt;3 up to 5 times ULN <b>or</b> total bilirubin &gt;1.5 up to 3 times ULN: Withhold ipilimumab; resume ipilimumab with complete or partial resolution (to grade 0 or 1) of hepatitis after corticosteroid taper.</p>
<p style="text-indent:-2em;margin-left:6em;">AST or ALT &gt;5 times ULN <b>or</b> total bilirubin &gt;3 times ULN: Permanently discontinue ipilimumab.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Immune-mediated hepatitis <b>with</b> tumor involvement of the liver/hepatocellular carcinoma (applies to hepatocellular carcinoma ipilimumab/nivolumab combination treatment):</i>
<b>Note: </b>When receiving combination therapy with ipilimumab and nivolumab, withhold or permanently discontinue both ipilimumab and nivolumab for adverse reactions meeting dosage modification recommendations (refer to Nivolumab monograph for information on nivolumab dosage adjustment for toxicity). If AST and ALT are ≤ ULN at baseline, follow recommendations for hepatitis <b>without</b> tumor involvement of the liver.</p>
<p style="text-indent:-2em;margin-left:6em;">If baseline AST or ALT &gt;1 up to 3 times ULN and increases to &gt;5 up to 10 times ULN or baseline AST or ALT &gt;3 up to 5 times ULN and increases to &gt;8 up to 10 times ULN: Withhold treatment. Resume treatment with complete or partial resolution (to grade 0 or 1) of hepatitis after corticosteroid taper.</p>
<p style="text-indent:-2em;margin-left:6em;">AST or ALT &gt;10 times ULN or total bilirubin &gt;3 times ULN: Discontinue permanently.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Additional</i>
<i> recommendations:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Grade 2 immune-mediated hepatitis:</i> Withhold immune checkpoint inhibitor (ICI); if no improvement within 3 to 5 days after ICI is withheld, consider initiation of corticosteroids (prednisone 0.5 to 1 mg/kg/day or equivalent) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Grade 3 or 4 immune-mediated hepatitis:</i> Withhold ICI; initiate corticosteroids (methylprednisolone 1 to 2 mg/kg or equivalent) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34724392']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34724392'])">Ref</a></span>). Based on data from a retrospective cohort study in patients with grade 3 or 4 immune-mediated hepatitis, initial treatment with methylprednisolone 1 mg/kg/day demonstrated similar time to ALT normalization (compared with higher methylprednisolone doses), while reducing the potential for corticosteroid-related complications (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34709662']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34709662'])">Ref</a></span>).</p></div>
<div class="block adr drugH1Div" id="F12706600"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (31% to 45%), skin rash (15% to 50%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Endocrine disease (4% to 28%), hyperglycemia (26%), hypocalcemia (20%), hyponatremia (26%), weight loss (7% to 32%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Colitis (8% to 31%), decreased appetite (14% to 24%), diarrhea (32% to 49%; grades ≥3: 5% to 10%), increased serum amylase (15% to 17%), increased serum lipase (24% to 26%), nausea (25% to 31%; grades ≥3: ≤2%), vomiting (13% to 17%; grades ≥3: ≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (41%; grades 3/4: 6%), lymphocytopenia (29%; grades 3/4: 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis (4% to 15%), increased serum alanine aminotransferase (29% to 46%), increased serum alkaline phosphatase (17% to 23%), increased serum aspartate aminotransferase (29% to 38%), increased serum bilirubin (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (41% to 51%), headache (33%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (16%), musculoskeletal pain (36%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (10% to 17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (22%, including productive cough), dyspnea (17%, including dyspnea on exertion), upper respiratory tract infection (17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (18%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Urticaria (2%), vitiligo (4% to 5%) (SITC [Brahmer 2021])</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Adrenocortical insufficiency (≤2%), Cushing syndrome (≤2%), hyperthyroidism (1%), hypothyroidism (5%), pituitary insufficiency (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Pancreatitis (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Hypogonadism (≤2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Cytopenia (3%), eosinophilia (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Infusion-related reaction (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Insomnia (10%), neuropathy (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury (2%) (SITC [Brahmer 2021]; Isik 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Pneumonitis (1%) (SITC [Brahmer 2021])</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Arteritis (temporal), myocarditis, pericarditis, peripheral vascular disease, vasculitis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema multiforme, psoriasis</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Thyroiditis</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Duodenitis, esophagitis, gastritis, ulcerative bowel lesion</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Aplastic anemia, lymphadenitis (histiocytic necrotizing [Kikuchi lymphadenitis])</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity angiitis</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Organ transplant rejection (solid), sarcoidosis</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Systemic inflammatory response syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Demyelinating disease, encephalitis, Guillain-Barre syndrome, meningitis, motor dysfunction, myasthenia (myasthenic syndrome), myasthenia gravis, paresis (nerve)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthritis, myelitis, myositis (including orbital), polymyalgia rheumatica, polymyositis, rhabdomyolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blepharitis, conjunctivitis, episcleritis, Graves ophthalmopathy, iritis, scleritis, uveitis</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Hypoacusis (neurosensory)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Renal failure syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Acute respiratory distress syndrome</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Miscellaneous: Vogt-Koyanagi-Harada disease</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Capillary leak syndrome (Hodi 2010)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pemphigoid (SITC [Brahmer 2021]), Stevens-Johnson syndrome (SITC [Brahmer 2021]), toxic epidermal necrolysis (SITC [Brahmer 2021])</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypophysitis (Hodi 2010), type 1 diabetes mellitus (SITC [Brahmer 2021])</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (Hodi 2010), cholangitis (SITC [Brahmer 2021]), cholecystitis (SITC [Brahmer 2021]), constipation (Hodi 2010), xerostomia (SITC [Brahmer 2021])</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemophagocytic lymphohistiocytosis (SITC [Brahmer 2021]; Hantel 2018), neutropenia (SITC [Brahmer 2021]), pure red cell aplasia (SITC [Brahmer 2021])</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatotoxicity (Chalasani 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Drug reaction with eosinophilia and systemic symptoms</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Graft-versus-host disease, Sjögren disease (SITC [Brahmer 2021])</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myalgia (SITC [Brahmer 2021])</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Dry eye syndrome (SITC [Brahmer 2021])</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchiolitis obliterans organizing pneumonia (Barjaktarevic 2013)</p></div>
<div class="block coi drugH1Div" id="F12706590"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer's US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Hypersensitivity to ipilimumab or any component of the formulation; active life-threatening autoimmune disease, or with organ transplantation graft where further immune activation is potentially imminently life-threatening</p></div>
<div class="block war drugH1Div" id="F12706591"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Adverse reactions (immune-mediated): Ipilimumab blocks T-cell inhibitory signals induced by the CTLA-4 pathway, thus removing inhibition of the immune response with the potential for induction of immune-mediated adverse reactions. Severe and fatal immune-mediated adverse effects may occur in any organ system or tissue. Reactions generally occur during treatment (may occur at any time after treatment initiation); reactions may also occur after ipilimumab discontinuation. Early identification and management of immune-mediated adverse reactions are necessary to ensure ipilimumab safety. Medically manage immune-mediated adverse reactions promptly and refer for specialty consultation as appropriate. Depending on the severity, withhold or permanently discontinue ipilimumab. In general, if treatment interruption or discontinuation are required, administer systemic corticosteroid therapy (1 to 2 mg/kg/day prednisone [or equivalent]) until improvement to ≤ grade 1. Upon improvement to grade 1 or lower, initiate corticosteroid taper and continue to taper over at least 1 month. Consider administration of other systemic immunosuppressants if immune-mediated adverse reaction is not controlled with corticosteroid therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Dermatologic toxicity: Ipilimumab may cause immune-mediated rash or dermatitis, including bullous and exfoliative dermatitis, Stevens-Johnson syndrome, toxic epidermal necrolysis, and drug reaction with eosinophilia and systemic symptoms (DRESS). Immune-mediated rash (including grade 2 or higher events) occurred with both single-agent ipilimumab and when used in combination with nivolumab. Higher ipilimumab doses were generally associated with an increased incidence of immune-mediated rash. Systemic corticosteroids were often used to manage immune-mediated rash; reactions resolved in a majority of those patients. In cases where ipilimumab was withheld and patients reinitiated treatment after symptom improvement, some of those patients experienced immune-mediated dermatologic toxicity recurrence.</p>
<p style="text-indent:-2em;margin-left:4em;">• Endocrinopathies: Immune-mediated endocrinopathies have occurred with single-agent ipilimumab and when used in combination with nivolumab, including grades 2 to 4 or fatal events. Some endocrinopathies have resulted in long-term hormone replacement therapy, hospitalizations, and management with systemic corticosteroids. Some patients reported resolution of endocrinopathy.</p>
<p style="text-indent:-2em;margin-left:6em;">- <i>Adrenal insufficiency:</i> Adrenal insufficiency, including grades 2 to 4, has occurred with single-agent ipilimumab and when used in combination with nivolumab. Adrenal insufficiency led to ipilimumab/nivolumab treatment interruption or discontinuation in a small number of patients. Most patients with adrenal insufficiency due to ipilimumab in combination with nivolumab received hormone replacement therapy and systemic corticosteroids. Adrenal insufficiency resolved in some patients. Some patients experienced a recurrence when ipilimumab and/or nivolumab treatment was restarted after symptom improvement.</p>
<p style="text-indent:-2em;margin-left:6em;">- <i>Diabetes mellitus:</i> Type 1 diabetes (including grade 2 to 4 events) has also been observed with ipilimumab in combination with nivolumab. Diabetes led to ipilimumab/nivolumab treatment interruption or discontinuation in some cases and systemic corticosteroids were required in some cases. Diabetes resolved in about one quarter of patients. Diabetes did not recur in patients whose treatment was restarted after symptom improvement.</p>
<p style="text-indent:-2em;margin-left:6em;">- <i>Hypophysitis:</i> Ipilimumab may cause immune-mediated hypophysitis, which may present with acute symptoms associated with mass effect, including headache, photophobia, or visual field defects. Hypophysitis may lead to hypopituitarism. Initiate hormone replacement as clinically indicated and, depending on the severity, withhold or discontinue ipilimumab; may also require treatment with systemic corticosteroids. Hypophysitis resolved in over half of patients. Some patients experienced a recurrence when treatment was restarted after symptom improvement.</p>
<p style="text-indent:-2em;margin-left:6em;">- <i>Thyroid disorders:</i> Immune-mediated hyperthyroidism, hypothyroidism, and thyroiditis have occurred with single-agent ipilimumab and when used in combination with nivolumab. Grades 2 and 3 hyperthyroidism have been observed. Although ipilimumab/nivolumab treatment interruption was necessary in some patients, no patients required ipilimumab discontinuation for hyperthyroidism. A thyroid synthesis inhibitor and/or systemic corticosteroids were necessary to manage hyperthyroidism in ~20% of patients. Hyperthyroidism resolved in most patients. Some patients experienced a recurrence when ipilimumab and/or nivolumab treatment was restarted after symptom improvement. Hypothyroidism (or thyroiditis resulting in hypothyroidism), including grade 2 and 3 events has been observed. Hypothyroidism led to ipilimumab/nivolumab treatment interruption or discontinuation in some patients. Most patients were managed with thyroid hormone replacement therapy; systemic corticosteroids were required in some patients. Hypothyroidism resolved in approximately one quarter of patients. Recurrence of hypothyroidism occurred rarely when ipilimumab and/or nivolumab treatment was restarted after symptom improvement. Thyroiditis has been reported with ipilimumab when used as a single-agent and when used in combination with nivolumab, including grade 2 and 3 thyroiditis. Thyroiditis led to ipilimumab/nivolumab treatment interruption or discontinuation in some cases; some patients required systemic corticosteroids. Thyroiditis resolved in a majority of patients. Thyroiditis did not recur in patients whose treatment was restarted after symptom improvement.</p>
<p style="text-indent:-2em;margin-left:6em;">- <i>Other endocrinopathies:</i> Cushing syndrome, hypogonadism, hypopituitarism, thyroidism, and Graves ophthalmopathy have also been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• GI toxicity: Ipilimumab may cause immune-mediated colitis, which may be fatal. Immune-mediated colitis (including grades 2 to 4 and fatal events) has occurred with single-agent ipilimumab and when used in combination with nivolumab. Systemic corticosteroids were necessary in 60% to 100% of patients with immune-mediated colitis (which resolved in 76% to 95% of these patients); some patients required coadministration of an additional immunosuppressant (with corticosteroids). Upon ipilimumab reinitiation (following therapy interruption for colitis and subsequent resolution), recurrence of colitis commonly occurred. Cytomegalovirus infection/reactivation has been reported in patients with corticosteroid-refractory immune-mediated diarrhea/colitis. In cases of corticosteroid-refractory diarrhea/colitis, consider repeating infectious workup to exclude alternative etiologies. Pancreatitis (including increased serum amylase and lipase levels), duodenitis, and gastritis, have also been reported (rarely).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Immune-mediated hepatitis (including grades 2 to 4 and fatal events) has occurred with single-agent ipilimumab and when used in combination with nivolumab. Hepatitis has led to ipilimumab treatment interruption and discontinuation. Systemic corticosteroids were used to manage immune-mediated hepatitis in many patients (which resolved in most of these patients); additional immunosuppressants were necessary in some cases. Upon ipilimumab reinitiation (following therapy interruption for colitis and subsequent resolution), recurrence of hepatitis occurred in some patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infusion-related reactions: Infusion-related reactions may occur with ipilimumab; may be severe.</p>
<p style="text-indent:-2em;margin-left:4em;">• Nephrotoxicity: Immune-mediated nephritis with renal dysfunction (including grade 2 to 4 events) has occurred with ipilimumab when used in combination with nivolumab, and has led to ipilimumab or nivolumab treatment interruption or discontinuation in some patients. Systemic corticosteroids were used to manage immune-mediated nephritis. Nephritis with renal dysfunction resolved in two-thirds of patients. Nephritis recurred in some patients whose treatment was restarted after symptom improvement.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular toxicity: Immune-mediated blepharitis, episcleritis, iritis, orbital myositis, scleritis, and uveitis have been observed (rarely) with ipilimumab. Some cases may be associated with retinal detachment. If uveitis occurs in combination with other immune-mediated adverse reactions, consider a Vogt-Koyanagi-Harada-like syndrome, which has been observed with ipilimumab.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pulmonary toxicity: Immune-mediated pneumonitis (including grade 2 to 4 events) has occurred with ipilimumab when used in combination with nivolumab; some cases were fatal. Pneumonitis has led to ipilimumab and nivolumab treatment interruption or discontinuation. Systemic corticosteroids were used to treat immune-mediated pneumonitis; some patients required coadministration of another immunosuppressant (with corticosteroids) to manage pneumonitis. Pneumonitis resolved in a majority of patients. In patients receiving ipilimumab with nivolumab for the treatment of non-small cell lung cancer, the median duration of pneumonitis was 1.5 months (range: 5 days to &gt;25 months). Some patients experienced recurrence when treatment was restarted after symptom improvement.</p>
<p style="text-indent:-2em;margin-left:4em;">• Other immune-mediated toxicities: Other clinically significant immune-mediated adverse reactions have been observed (rarely although sometimes fatal) with ipilimumab (either as a single agent or in combination with nivolumab), including autoimmune neuropathy, meningitis, encephalitis, neurosensory hypoacusis, myelitis and demyelination, myasthenic syndrome/myasthenia gravis, Guillain-Barré syndrome, nerve paresis, motor dysfunction, angiopathy, myocarditis, pericarditis, temporal arteritis, vasculitis, arthritis, myositis, polymyalgia rheumatica, polymyositis, rhabdomyolysis, aplastic anemia, conjunctivitis, cytopenias, eosinophilia, histiocytic necrotizing lymphadenitis (Kikuchi lymphadenitis), hypersensitivity vasculitis, psoriasis, sarcoidosis, systemic inflammatory response syndrome, and solid organ transplant rejection.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Disease-related concerns: </b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Hematopoietic stem cell transplant: Serious and potentially fatal graft-vs-host disease (GVHD) can occur in patients receiving ipilimumab either before or after allogeneic hematopoietic stem cell transplantation (HSCT). These complications may occur despite intervening therapy between CTLA-4 receptor blocking antibody and allogeneic HSCT. Monitor for evidence of GVHD and manage promptly. Consider the benefit versus risks of ipilimumab treatment following allogeneic HSCT.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myasthenia gravis: Checkpoint inhibitors may worsen or precipitate new myasthenia gravis (MG), especially within the first 16 weeks of treatment; use with caution. Patients with well-controlled MG may be considered for checkpoint inhibitor therapy if MG treatment is maintained (or reinitiated in patients whose MG is in remission), combination therapy (eg, anti–CTLA-4 with anti–PD-a/PD-L1 monoclonal antibodies) is avoided, and respiratory and bulbar function are closely followed. In patients who develop overt MG during checkpoint inhibitor therapy, early aggressive treatment with plasma exchange or IVIG in combination with high-dose corticosteroids may be required (AAN [Narayanaswami 2021]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Special populations:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adults: In patients with non-small cell lung cancer (NSCLC) who received ipilimumab/nivolumab or ipilimumab/nivolumab with platinum-based doublet chemotherapy, patients ≥75 years of age experienced a higher discontinuation rate due to adverse reactions relative to all patients with NSCLC who received ipilimumab/nivolumab. In the esophageal squamous cell carcinoma (ESCC) ipilimumab/nivolumab study, patients ≥75 years of age experienced a higher discontinuation rate due to adverse reactions relative to all patients with ESCC who received ipilimumab/nivolumab. In the malignant pleural mesothelioma study of ipilimumab in combination with nivolumab, patients ≥75 years of age experienced a higher rate of serious adverse reactions and discontinuation due to adverse reactions.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Other warnings/precautions:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Select patients for first-line ipilimumab/nivolumab treatment of metastatic NSCLC based on PD-L1 expression. Information on tests to detect PD-L1 expression may be found at <a href="/external-redirect?target_url=http%3A%2F%2Fwww.fda.gov%2Fcompaniondiagnostics&amp;token=SHauxSdf9qNc6lLK16E8IFPiEHUnQ%2FrX%2FFBRnAtp%2BYOOMBGgh36vrA79ff4L%2FMZW&amp;TOPIC_ID=116880" target="_blank">http://www.fda.gov/companiondiagnostics</a>.</p></div>
<div class="block foc drugH1Div" id="F12706635"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Yervoy: 50 mg/10 mL (10 mL); 200 mg/40 mL (40 mL) [contains polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F12706584"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16322871"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Yervoy Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/10 mL (per mL): $1,023.90</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg/40 mL (per mL): $1,023.90</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871223"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Yervoy: 5 mg/mL (10 mL, 40 mL) [contains polysorbate 80]</p></div>
<div class="block admp drugH1Div" id="F52614467"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">IV: Infuse over 30 minutes (refer to specific protocols); administer through a sterile, non-pyrogenic, low protein-binding in-line filter. Do not administer with other medications. Flush with NS or D5W after each ipilimumab infusion.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i> Combination therapy with nivolumab:</i> When administered in combination with nivolumab, infuse nivolumab first followed by ipilimumab on the same day. Use separate infusion bags and filters for each infusion.</p></div>
<div class="block adm drugH1Div" id="F10940813"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Infuse through a sterile, nonpyrogenic, low protein-binding in-line filter. Do not administer with other medications. Flush with NS or D5W after each ipilimumab infusion.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Colorectal cancer (metastatic), esophageal squamous cell carcinoma, hepatocellular carcinoma, malignant pleural mesothelioma, melanoma (unresectable/metastatic), non–small cell lung cancer, or renal cell carcinoma (advanced): </i>Infuse over 30 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Melanoma (adjuvant treatment):</i> Infuse over 90 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Monitor for infusion reactions. Interrupt or slow the infusion for grade 1 or 2 infusion-related reactions; permanently discontinue for grade 3 or 4 infusion-related reactions.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Combination therapy with nivolumab:</i> When administered in combination with nivolumab, infuse nivolumab first, followed by ipilimumab (on the same day as nivolumab). Use separate infusion bags and filters for each infusion.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Combination therapy with nivolumab and platinum-based doublet chemotherapy:</i> When administered in combination with nivolumab and platinum-based doublet chemotherapy, infuse nivolumab first, followed by ipilimumab, and then the platinum-based doublet chemotherapy (all on the same day). Use separate infusion bags and filters for each infusion.</p></div>
<div class="block sts drugH1Div" id="F12706606"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store intact vials at 2°C to 8°C (36°F to 46°F); do not freeze. Protect from light. Do not shake. Prior to preparation, allow vials to sit at room temperature for ~5 minutes. Solutions diluted for infusion in NS or D5W are stable for up to 24 hours (from time of preparation to time of infusion) refrigerated or at room temperature.</p></div>
<div class="block meg drugH1Div" id="F12707872"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F125377s129lbl.pdf%23page%3D72&amp;token=xdnRJDsKi92bvtc7y876zWxEdlhLeRU2ctU1d6c7Uy2rZijWi0kSv8IZE7G7mr9dtEXVemqqNZidmzS3S%2BK3TxuR4I7LsFjguYKYaqHicA1duQUgQ1%2B8RGbjIWm7iGvV&amp;TOPIC_ID=116880" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125377s129lbl.pdf#page=72</a>, must be dispensed with this medication.</p></div>
<div class="block usep drugH1Div" id="F53570893"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>Indications including pediatric patients:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Treatment of microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan, in combination with nivolumab; treatment of unresectable or metastatic melanoma as a single agent or in combination with nivolumab (All indications: FDA approved in ages ≥12 years and adults). <b>Note:</b> FDA approval for MSI-H or dMMR metastatic CRC is through an accelerated process; continued approval is dependent upon verification of clinical benefit in further trials.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Indications approved only in adults:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Adjuvant treatment of cutaneous melanoma in patients with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy; treatment of intermediate or poor risk, previously untreated advanced renal cell carcinoma (in combination with nivolumab); treatment of hepatocellular carcinoma (in combination with nivolumab) in patients who have been previously treated with sorafenib; first-line treatment of metastatic non-small cell lung cancer (in combination with nivolumab) in patients whose tumors express PD-L1 (≥1%) as determined by an approved test, and with no EGFR or ALK genomic tumor aberrations; first-line treatment of metastatic or recurrent non-small cell lung cancer (in combination with nivolumab and 2 cycles of platinum doublet chemotherapy) in patients with no EGFR or ALK genomic tumor aberrations; first-line treatment of unresectable malignant pleural mesothelioma (in combination with nivolumab); first-line treatment of unresectable advanced or metastatic esophageal squamous cell carcinoma (in combination with nivolumab) (All indications: FDA approved in adults).</p></div>
<div class="block mst drugH1Div" id="F10940805"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Ipilimumab may be confused with dostarlimab, dupilumab, idaruCIZUmab, isatuximab, nivolumab, tremelimumab.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299539"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F12757387"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetaminophen: May diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antibiotics: May diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). Management: Carefully consider the need for corticosteroids, at doses of a prednisone-equivalent of 10 mg or more per day, during the initiation of immune checkpoint inhibitor therapy. Use of corticosteroids to treat immune related adverse events is still recommended<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inhibitors of the Proton Pump (PPIs and PCABs): May diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketoconazole (Systemic): Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies) may enhance the hepatotoxic effect of Ketoconazole (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vemurafenib: Ipilimumab may enhance the hepatotoxic effect of Vemurafenib.  Management: Consider alternatives to this combination when possible.  Use of this combination should only be undertaken with extra close monitoring of liver function (hepatic transaminases and bilirubin) and signs/symptoms of hepatotoxicity.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49307958"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Verify pregnancy status prior to treatment initiation in patients who could become pregnant. Patients who could become pregnant should use effective contraception during treatment and for 3 months following the last ipilimumab dose.</p>
<p style="text-indent:0em;margin-top:2em;">Pituitary dysfunction, secondary to autoimmune hypophysitis, may occur with ipilimumab therapy; male and female fertility may be impaired (Grunewald 2015).</p></div>
<div class="block pri drugH1Div" id="F12706587"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on the mechanism of action and findings from animal reproduction studies, in utero exposure to ipilimumab may cause fetal harm. Ipilimumab is a humanized monoclonal antibody (IgG<sub>1</sub>). Potential placental transfer of human IgG is dependent upon the IgG subclass and gestational age, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis (Palmeira 2012; Pentsuk 2009).</p>
<p style="text-indent:0em;margin-top:2em;">Information related to ipilimumab in pregnancy is limited to case reports describing use in patients with metastatic melanoma (Burotto 2018; Mehta 2018; Menzer 2018).</p>
<p style="text-indent:0em;margin-top:2em;">Guidelines are available for the diagnosis, treatment, and follow-up of cancer during pregnancy; the guidelines recommend referral to a facility with expertise in cancer during pregnancy and encourage a multidisciplinary team (obstetrician, neonatologist, oncology team) (ESMO [Peccatori 2013]; Swetter 2019). Until additional information is available, use of ipilimumab for the treatment of melanoma during pregnancy is not recommended (ESMO [Peccatori 2013]).</p>
<p style="text-indent:0em;margin-top:2em;">A pregnancy registry has been established to collect information about women exposed to ipilimumab during pregnancy. Ipilimumab exposures during pregnancy should be reported to the manufacturer by calling 1-844-593-7869.</p></div>
<div class="block mopp drugH1Div" id="F53570895"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor liver function and evaluate for signs of hepatotoxicity prior to each dose; if hepatotoxicity develops, liver function should be monitored more frequently until resolution. If LFTs are &gt;8 times ULN, monitor every other day until they begin to fall, then weekly until normal (Weber 2012). Monitor serum chemistries and ACTH prior to each dose. Monitor SCr (baseline and periodic). Monitor for signs of hypophysitis, adrenal insufficiency, and thyroid disorders (eg, abdominal pain, fatigue, headache, hypotension, mental status changes, unusual bowel habits). Monitor thyroid-stimulating hormone, free T<sub>4,</sub> and cortisol levels (morning) at baseline, prior to dose, and as clinically indicated. Monitor for signs and symptoms of enterocolitis (abdominal pain, blood or mucus in stool or diarrhea) and intestinal perforation (peritoneal signs, ileus). Monitor for rash and pruritus. Monitor for signs of motor or sensory neuropathy (unilateral or bilateral weakness, sensory changes, or paresthesia). Monitor for ocular toxicity at baseline, then at 4 to 8 weeks with further evaluations as clinically indicated (Renouf 2012). Monitor for signs/symptoms of pneumonitis, encephalitis, and infusion-related reactions. In adult patients, additional cancer-specific monitoring parameters may be necessary (refer to specific protocols or manufacturer labeling).</p></div>
<div class="block pha drugH1Div" id="F12706610"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Ipilimumab is a recombinant human IgG1 immunoglobulin monoclonal antibody that binds to the cytotoxic T-lymphocyte associated antigen 4 (CTLA-4). CTLA-4 is a down-regulator of T-cell activation pathways. Blocking CTLA-4 allows for enhanced T-cell activation and proliferation. In melanoma, ipilimumab may indirectly mediate T-cell immune responses against tumors. Combining ipilimumab (anti-CTLA-4) with nivolumab (anti-PD-1) results in enhanced T-cell function that is greater than that of either antibody alone, resulting in improved antitumor responses in metastatic melanoma and advanced renal cell carcinoma.</p></div>
<div class="block phk drugH1Div" id="F12706620"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Terminal: 15.4 days.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Clearance: Ipilimumab monotherapy: 16.8 mL/hour; compared to ipilimumab monotherapy, ipilimumab clearance is unchanged when administered every 3 weeks in combination with nivolumab, increased 30% when administered every 6 weeks in combination with nivolumab, and increased 22% when administered every 6 weeks in combination with nivolumab and platinum-based doublet chemotherapy.</p></div>
<div class="block phksp drugH1Div" id="F51193241"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Body weight: Clearance is increased with increasing body weight.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F13276709"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Yervoy</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Yervoy</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Yervoy</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Yervoy</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Yervoy</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Yervoy</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Yervoy</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Yervoy</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Yervoy</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Yervoy</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Yervoy</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Yervoy</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Yervoy</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Yervoy</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Yervoy</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Yervoy</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Yervoy</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Yervoy</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Yervoy</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Yervoy</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Yervoy</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Yervoy</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Yervoy</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Yervoy</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Yervoy</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Yervoy</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Yervoy</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Yervoy</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Yervoy</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Yervoy</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Yervoy</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Yervoy</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Yervoy</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Yervoy</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Yervoy</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Yervoy</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Yervoy</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Yervoy</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Yervoy</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Yervoy</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Yervoy</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Yervoy</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Yervoy</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Yervoy</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Yervoy</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Yervoy</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Yervoy</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Yervoy</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Yervoy</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Yervoy</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics.</i> 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipilimumab-pediatric-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27269741">
<a name="27269741"></a>Antonia SJ, López-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. <i>Lancet Oncol.</i> 2016;17(7):883-895.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipilimumab-pediatric-drug-information/abstract-text/27269741/pubmed" id="27269741" target="_blank">27269741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27918725">
<a name="27918725"></a>Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol.</i> 2017;35(8):893-911. doi:10.1200/JCO.2016.70.5400<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipilimumab-pediatric-drug-information/abstract-text/27918725/pubmed" id="27918725" target="_blank">27918725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Atkins.1">
<a name="Atkins.1"></a>Atkins MB. Overview of the treatment of renal cell carcinoma. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 23, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33485464">
<a name="33485464"></a>Baas P, Scherpereel A, Nowak A, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet.</i> 2021;397(10272):375-386. doi:10.1016/S0140-6736(20)32714-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipilimumab-pediatric-drug-information/abstract-text/33485464/pubmed" id="33485464" target="_blank">33485464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23460165">
<a name="23460165"></a>Barjaktarevic IZ, Qadir N, Suri A, Santamauro JT, Stover D. Organizing pneumonia as a side effect of ipilimumab treatment of melanoma. <i>Chest</i>. 2013;143(3):858-861.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipilimumab-pediatric-drug-information/abstract-text/23460165/pubmed" id="23460165" target="_blank">23460165</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34172516">
<a name="34172516"></a>Brahmer JR, Abu-Sbeih H, Ascierto PA, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. <i>J Immunother Cancer</i>. 2021;9(6):e002435. doi:10.1136/jitc-2021-002435<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipilimumab-pediatric-drug-information/abstract-text/34172516/pubmed" id="34172516" target="_blank">34172516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31433922">
<a name="31433922"></a>Burch HB. Drug effects on the thyroid. <i>N Engl J Med</i>. 2019;381(8):749‐761. doi:10.1056/NEJMra1901214<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipilimumab-pediatric-drug-information/abstract-text/31433922/pubmed" id="31433922" target="_blank">31433922</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30262400">
<a name="30262400"></a>Burotto M, Gormaz JG, Samtani S, et al. Viable Pregnancy in a patient with metastatic melanoma treated with double checkpoint immunotherapy. <i>Semin Oncol</i>. 2018;45(3):164-169. doi:10.1053/j.seminoncol.2018.03.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipilimumab-pediatric-drug-information/abstract-text/30262400/pubmed" id="30262400" target="_blank">30262400</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product.<i> MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipilimumab-pediatric-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33929376">
<a name="33929376"></a>Chalasani NP, Maddur H, Russo MW, Wong RJ, Reddy KR; Practice parameters committee of the American College of Gastroenterology. ACG clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2021;116(5):878-898. doi:10.14309/ajg.0000000000001259<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipilimumab-pediatric-drug-information/abstract-text/33929376/pubmed" id="33929376" target="_blank">33929376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36190525">
<a name="36190525"></a>Davis KL, Fox E, Isikwei E, et al. A phase I/II trial of nivolumab plus ipilimumab in children and young adults with relapsed/refractory solid tumors: a Children's Oncology Group Study ADVL1412. <i>Clin Cancer Res</i>. 2022;28(23):5088-5097. doi:10.1158/1078-0432.CCR-22-2164<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipilimumab-pediatric-drug-information/abstract-text/36190525/pubmed" id="36190525" target="_blank">36190525</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35108470">
<a name="35108470"></a>Doki Y, Ajani JA, Kato K, et al; CheckMate 648 Trial Investigators. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. <i>N Engl J Med</i>. 2022;386(5):449-462. doi:10.1056/NEJMoa2111380<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipilimumab-pediatric-drug-information/abstract-text/35108470/pubmed" id="35108470" target="_blank">35108470</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27717298">
<a name="27717298"></a>Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy.<i> N Engl J Med.</i> 2016;375(19):1845-1855.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipilimumab-pediatric-drug-information/abstract-text/27717298/pubmed" id="27717298" target="_blank">27717298</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-George.1">
<a name="George.1"></a>George D, Jonasch E. Systemic therapy of advanced clear cell renal carcinoma. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 23, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33939491">
<a name="33939491"></a>Griggs JJ, Bohlke K, Balaban EP, et al. Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO guideline update. <i>J Clin Oncol</i>. 2021;39(18):2037-2048. doi:10.1200/JCO.21.00471<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipilimumab-pediatric-drug-information/abstract-text/33939491/pubmed" id="33939491" target="_blank">33939491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25819232">
<a name="25819232"></a>Grunewald S, Jank A. New systemic agents in dermatology with respect to fertility, pregnancy, and lactation. <i>J Dtsch Dermatol Ges</i>. 2015;13(4):277-290. doi:10.1111/ddg.12596<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipilimumab-pediatric-drug-information/abstract-text/25819232/pubmed" id="25819232" target="_blank">25819232</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22010182">
<a name="22010182"></a>Hamnvik OP, Larsen PR, Marqusee E. Thyroid dysfunction from antineoplastic agents. <i>J Natl Cancer Inst</i>. 2011;103(21):1572-1587.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipilimumab-pediatric-drug-information/abstract-text/22010182/pubmed" id="22010182" target="_blank">22010182</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30012206">
<a name="30012206"></a>Hantel A, Gabster B, Cheng JX, Golomb H, Gajewski TF. Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab. <i>J Immunother Cancer</i>. 2018;6(1):73.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipilimumab-pediatric-drug-information/abstract-text/30012206/pubmed" id="30012206" target="_blank">30012206</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Health.Canada.1">
<a name="Health.Canada.1"></a>Healthy Canadians Recalls &amp; Alerts: Summary Safety Review - Opdivo (nivolumab) and Yervoy (ipilimumab) used alone, or in combination - Health Canada. Health Canada website. Available at: <a href="https://hpr-rps.hres.ca/reg-content/summary-safety-review-detail.php?lang=en&amp;linkID=SSR00225" target="_blank">https://hpr-rps.hres.ca/reg-content/summary-safety-review-detail.php?lang=en&amp;linkID=SSR00225</a>. Published: June 24, 2019. Accessed: June 28, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31562796">
<a name="31562796"></a>Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. <i>N Engl J Med</i>. 2019;381(21):2020‐2031. doi:10.1056/NEJMoa1910231<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipilimumab-pediatric-drug-information/abstract-text/31562796/pubmed" id="31562796" target="_blank">31562796</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20525992">
<a name="20525992"></a>Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. <i>N Engl J Med</i>. 2010;363(8):711-723.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipilimumab-pediatric-drug-information/abstract-text/20525992/pubmed" id="20525992" target="_blank">20525992</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26282644">
<a name="26282644"></a>Horvat TZ, Adel NG, Dang TO, et al. Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center.<i> J Clin Oncol</i>. 2015;33(28):3193-3198.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipilimumab-pediatric-drug-information/abstract-text/26282644/pubmed" id="26282644" target="_blank">26282644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipilimumab-pediatric-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipilimumab-pediatric-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Isik.2021">
<a name="Isik.2021"></a>Isik B, Alexander MP, Manohar S, et al. Biomarkers, clinical features and rechallenge for immune checkpoint inhibitor renal immune-related adverse events. <i>Kidney International Reports (</i>2021). doi: https://doi.org/10.1016/j.ekir.2021.01.013</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36108657">
<a name="36108657"></a>Kim S, Wuthrick E, Blakaj D, et al. Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial. <i>Lancet</i>. 2022;400(10357):1008-1019. doi:10.1016/S0140-6736(22)01659-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipilimumab-pediatric-drug-information/abstract-text/36108657/pubmed" id="36108657" target="_blank">36108657</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26027431">
<a name="26027431"></a>Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. <i>N Engl J Med</i>. 2015;373(1):23-34.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipilimumab-pediatric-drug-information/abstract-text/26027431/pubmed" id="26027431" target="_blank">26027431</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31562797">
<a name="31562797"></a>Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. <i>N Engl J Med</i>. 2019;381(16):1535-1546. doi:10.1056/NEJMoa1910836<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipilimumab-pediatric-drug-information/abstract-text/31562797/pubmed" id="31562797" target="_blank">31562797</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34709662">
<a name="34709662"></a>Li M, Wong D, Vogel AS, et al. Effect of corticosteroid dosing on outcomes in high-grade immune checkpoint inhibitor hepatitis. <i>Hepatology</i>. 2022;75(3):531-540. doi:10.1002/hep.32215<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipilimumab-pediatric-drug-information/abstract-text/34709662/pubmed" id="34709662" target="_blank">34709662</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipilimumab-pediatric-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36017568">
<a name="36017568"></a>Lyon AR, López-Fernández T, Couch LS, et al; ESC Scientific Document Group. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). <i>Eur Heart J.</i> 2022;43(41):4229-4361. doi:10.1093/eurheartj/ehac244<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipilimumab-pediatric-drug-information/abstract-text/36017568/pubmed" id="36017568" target="_blank">36017568</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22456429">
<a name="22456429"></a>Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. <i>Lancet Oncol</i>. 2012;13(5):459-465.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipilimumab-pediatric-drug-information/abstract-text/22456429/pubmed" id="22456429" target="_blank">22456429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30241195">
<a name="30241195"></a>Mehta A, Kim KB, Minor DR. Case report of a pregnancy during ipilimumab therapy. <i>J Glob Oncol</i>. 2018;4:1-3. doi:10.1200/JGO.17.00019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipilimumab-pediatric-drug-information/abstract-text/30241195/pubmed" id="30241195" target="_blank">30241195</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30454709">
<a name="30454709"></a>Menzer C, Beedgen B, Rom J, et al. Immunotherapy with ipilimumab plus nivolumab in a stage IV melanoma patient during pregnancy. <i>Eur J Cancer</i>. 2018;104:239-242. doi:10.1016/j.ejca.2018.09.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipilimumab-pediatric-drug-information/abstract-text/30454709/pubmed" id="30454709" target="_blank">30454709</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31427204">
<a name="31427204"></a>Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. <i>Lancet Oncol</i>. 2019;20(10):1370‐1385. doi:10.1016/S1470-2045(19)30413-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipilimumab-pediatric-drug-information/abstract-text/31427204/pubmed" id="31427204" target="_blank">31427204</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29562145">
<a name="29562145"></a>Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. <i>N Engl J Med</i>. 2018;378(14):1277-1290.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipilimumab-pediatric-drug-information/abstract-text/29562145/pubmed" id="29562145" target="_blank">29562145</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33144515">
<a name="33144515"></a>Narayanaswami P, Sanders DB, Wolfe G, et al. International consensus guidance for management of myasthenia gravis: 2020 update. <i>Neurology</i>. 2021;96(3):114-122. doi:10.1212/WNL.0000000000011124<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipilimumab-pediatric-drug-information/abstract-text/33144515/pubmed" id="33144515" target="_blank">33144515</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29355075">
<a name="29355075"></a>Overman MJ, Lonardi S, Wong KYM, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. <i>J Clin Oncol.</i> 2018;36(8):773-779. doi:10.1200/JCO.2017.76.9901<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipilimumab-pediatric-drug-information/abstract-text/29355075/pubmed" id="29355075" target="_blank">29355075</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Owonikoko.2019">
<a name="Owonikoko.2019"></a>Owonikoko TK, Kim HR, Govindan N, et al. Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): results from the double-blind, randomized phase III CheckMate 451 study [abstract from 2019 European Lung Cancer Congress].<i> Ann Onc.</i> 2019;30(S2):LBA1_PR. doi:10.1093/annonc/mdz094</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22235228">
<a name="22235228"></a>Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. <i>Clin Dev Immunol</i>. 2012;2012:985646.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipilimumab-pediatric-drug-information/abstract-text/22235228/pubmed" id="22235228" target="_blank">22235228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33476593">
<a name="33476593"></a>Paz-Ares L, Ciuleanu TE, Cobo M, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. <i>Lancet Oncol.</i> 2021:S1470-2045(20)30641-0. doi:10.1016/S1470-2045(20)30641-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipilimumab-pediatric-drug-information/abstract-text/33476593/pubmed" id="33476593" target="_blank">33476593</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23813932">
<a name="23813932"></a>Peccatori FA, Azim HA Jr, Orecchia R, et al. Cancer, pregnancy and fertility: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. <i>Ann Oncol</i>. 2013;24(suppl 6):vi160-vi170. doi:10.1093/annonc/mdt199<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipilimumab-pediatric-drug-information/abstract-text/23813932/pubmed" id="23813932" target="_blank">23813932</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19626656">
<a name="19626656"></a>Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. <i>Birth Defects Res B Dev Reprod Toxicol</i>. 2009;86(4):328-344.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipilimumab-pediatric-drug-information/abstract-text/19626656/pubmed" id="19626656" target="_blank">19626656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35124183">
<a name="35124183"></a>Peters S, Scherpereel A, Corenelissen R, et al. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. <i>Ann Oncol.</i> 2022;33(5):488-499. doi:10.1016/j.annonc.2022.01.074<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipilimumab-pediatric-drug-information/abstract-text/35124183/pubmed" id="35124183" target="_blank">35124183</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22271879">
<a name="22271879"></a>Prieto PA, Yang JC, Sherry RM, et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. <i>Clin Cancer Res</i>. 2012;18(7):2039-2047.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipilimumab-pediatric-drug-information/abstract-text/22271879/pubmed" id="22271879" target="_blank">22271879</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35728020">
<a name="35728020"></a>Rathmell WK, Rumble RB, Van Veldhuizen PJ, et al. Management of metastatic clear cell renal cell carcinoma: ASCO guideline. <i>J Clin Oncol</i>. 2022;40(25):2957-2995. doi:10.1200/JCO.22.00868<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipilimumab-pediatric-drug-information/abstract-text/35728020/pubmed" id="35728020" target="_blank">35728020</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31629915">
<a name="31629915"></a>Ready NE, Ott PA, Hellmann MD, et al. Nivolumab monotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer: results from the CheckMate 032 randomized cohort. <i>J Thorac Oncol</i>. 2020;15(3):426-435. doi:10.1016/j.jtho.2019.10.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipilimumab-pediatric-drug-information/abstract-text/31629915/pubmed" id="31629915" target="_blank">31629915</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22649132">
<a name="22649132"></a>Renouf D, Velazquez-Martin JP, Simpson R, et al. Ocular toxicity of targeted therapies. <i>J Clin Oncol</i>. 2012;30(26):3277-3286.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipilimumab-pediatric-drug-information/abstract-text/22649132/pubmed" id="22649132" target="_blank">22649132</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27664248">
<a name="27664248"></a>Roila F, Molassiotis A, Herrstedt J, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. <i>Ann Oncol</i>. 2016;27(suppl 5):v119-v133.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipilimumab-pediatric-drug-information/abstract-text/27664248/pubmed" id="27664248" target="_blank">27664248</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34724392">
<a name="34724392"></a>Schneider BJ, Naidoo J, Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. <i>J Clin Oncol</i>. 2021;39(36):4073-4126. doi:10.1200/JCO.21.01440<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipilimumab-pediatric-drug-information/abstract-text/34724392/pubmed" id="34724392" target="_blank">34724392</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipilimumab-pediatric-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30392755">
<a name="30392755"></a>Swetter SM, Tsao H, Bichakjian CK, et al. Guidelines of care for the management of primary cutaneous melanoma. <i>J Am Acad Dermatol</i>. 2019;80(1):208-250. doi:10.1016/j.jaad.2018.08.055<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipilimumab-pediatric-drug-information/abstract-text/30392755/pubmed" id="30392755" target="_blank">30392755</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31880964">
<a name="31880964"></a>Tarhini AA, Lee SJ, Hodi FS, et al. Phase III study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma: North American Intergroup E1609. <i>J Clin Oncol</i>. 2020;38(6):567-575. doi:10.1200/JCO.19.01381<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipilimumab-pediatric-drug-information/abstract-text/31880964/pubmed" id="31880964" target="_blank">31880964</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30134131">
<a name="30134131"></a>Tawbi HA, Forsyth PA, Algazi A, et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. <i>N Engl J Med</i>. 2018;379(8):722-730. doi:10.1056/NEJMoa1805453<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipilimumab-pediatric-drug-information/abstract-text/30134131/pubmed" id="30134131" target="_blank">30134131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22124094">
<a name="22124094"></a>Vogel WV, Guislain A, Kvistborg P, et al. Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission. <i>J Clin Oncol</i>. 2012;30(2):e7-e10.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipilimumab-pediatric-drug-information/abstract-text/22124094/pubmed" id="22124094" target="_blank">22124094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22614989">
<a name="22614989"></a>Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. <i>J Clin Oncol</i>. 2012;30(21):2691-2697.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipilimumab-pediatric-drug-information/abstract-text/22614989/pubmed" id="22614989" target="_blank">22614989</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20004617">
<a name="20004617"></a>Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. <i>Lancet Oncol</i>. 2010;11(2):155-164.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipilimumab-pediatric-drug-information/abstract-text/20004617/pubmed" id="20004617" target="_blank">20004617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20957980">
<a name="20957980"></a>Wolchok JD, Weber JS, Hamid O, et al. Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. <i>Cancer Immun</i>. 2010;10:9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ipilimumab-pediatric-drug-information/abstract-text/20957980/pubmed" id="20957980" target="_blank">20957980</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pau.1">
<a name="Pau.1"></a>Yau T, Kang YK, Kim TY, et al. Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): results from CheckMate 040 [abstract 4012 from 2019 ASCO annual meeting]. <i>J Clin Oncol</i>. 2019;37(15s):4012. https://meetinglibrary.asco.org/record/173194/abstract. Accessed May 27, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Yervoy.1">
<a name="Yervoy.1"></a>Yervoy (ipilimumab) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb; February 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Yervoy.2">
<a name="Yervoy.2"></a>Yervoy (ipilimumab) [product monograph]. Montreal, Canada: Bristol-Myers Squibb Canada Co; November 2022.</div>
</li></ol></div><div id="topicVersionRevision">Topic 116880 Version 135.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
